Table 4 Information on health-related quality of life (QOL) and prevalence of depressive symptoms at study baseline
LHON patients (n = 34) | Asymptomatic LHON mutation carriers (n = 37) | General population | |
|---|---|---|---|
SF-12 v2 at study baseline | |||
(68/71 with data) | 33/34 | 35/37 | |
MCS | 49.5 ± 10.3 | 41.4 ± 9.5 | N/A |
M | 48.7 (± 10.6) | 50.38 (± 7.0) | 50.4 (± 9.9) |
F | 53.3 (± 8.9) | 39.59 (± 8.9)* | 48.4 (± 9.6) |
PCS | 46.7 ± 6.9 | 54.3 ± 9.6 | N/A |
M | 47.3 (± 6.6) | 57.1 (± 3.5)* | 50.6 (± 10.2) |
F | 43.9 (± 8.4) | 53.7 (± 10.4) | 48.7 (± 9.6) |
BDI at study baseline | |||
(63/71 with data) | 30/34 | 33/37 | |
Depressive symptoms: | |||
Severe | 0 | 0 | (Depression 16–20%;10% F; 6% M)) |
Moderate | 2 (7%) [2M] | 2 (6%) [2F] | |
Mild | 0 | 10 (30%) [10F] | |
Depression score | 4.5 ± 6.0 | 8.1 ± 6.0* |